Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and economic growth for Americans. Some may not think about manufacturing when they think about their medicines, but America’s biopharmaceutical sector has a significant advanced manufacturing footprint.
The U.S. biopharmaceutical industry leads in developing and bringing innovative medicines to patients around the world, and is also a global leader in biopharmaceutical manufacturing, with companies building, employing and innovating in communities across the country. In 2018, biopharmaceutical research and development (R&D) and manufacturing generated $54.7 billion in exports — an all-time high. Biopharmaceutical companies also operate over 1,100 manufacturing facilities across the U.S. and manufacture 16 of the top 20 brand medicines here in the USA.
The biopharmaceutical industry also stands out as a leader in manufacturing in several important ways, including:
- Significant economic impacts: Between 2000 and 2016 the U.S. biopharmaceutical sector outpaced all other manufacturing industries in economic output growth. Further, the value of the sector’s labor productivity is nearly three times greater than that of other sectors with a significant manufacturing footprint, and biopharmaceutical manufacturing wages are 72% higher than the average wage for all U.S. manufacturing.
- Advanced, innovation-led industry: Biopharmaceutical manufacturing is considered an “advanced” manufacturing industry, driven by high levels of innovation and R&D. The sector’s R&D intensity is 5 times greater than the average R&D intensity for all U.S. manufacturing industries. As both a leading manufacturer and an advanced, innovation-intensive industry, the biopharmaceutical sector is able to provide high-quality employment across a range of fields, power groundbreaking R&D and drive sustained growth across the U.S. economy.
- Specialized and highly regulated manufacturing processes: Biopharmaceutical manufacturing is complex, conducted under particularly strict regulatory and quality standards, and is the critical link between the discovery of a new medicine and patients. Biopharmaceutical manufacturing processes and technologies must constantly evolve to keep pace with innovative breakthroughs and scientific advances made possible through sustained R&D. As a result, the manufacturing solutions found within biopharmaceutical sector–such as single-use systems, continuous manufacturing and advanced purification technologies—are particularly notable.
Undoubtedly, the United States biopharmaceutical industry is a global manufacturing powerhouse, contributing to the American economy and workforce, and supporting patients around the world. However, this seat at the head of the table is not to be taken for granted. Increasingly, international competitors are challenging the U.S. for its position as the world’s leading biopharmaceutical innovator. To maintain this foothold and sustain benefits reaped from American biopharmaceutical manufacturing, it’s imperative that policymakers support pro-innovation policies and trade agreements that foster a strong intellectual property system, promote a well-functioning and evidence-based regulatory system, and advance policies that support future breakthroughs.
Megan Van Etten
Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Megan Van Etten
ICYMI: Pennsylvania shows what biopharmaceutical innovation can deliver
Staffing up: Building the future biopharma workforce to keep America in the lead
MFN price controls threaten American jobs and the U.S. economy
America Cures: Championing U.S. leadership in medical innovation
Middlemen mark up drug prices and keep discounts meant for you
Celebrating STEM Day: Investing in America’s innovators
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
New research: Industry sponsored clinical trials contribute billions to state economies
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
Biopharmaceutical industry supports jobs and drives economic growth across the United States
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
New data: America is an API powerhouse
Biopharmaceutical manufacturing companies continue to expand their economic footprint across the United States
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
U.S. biopharmaceutical exports support jobs, innovation
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
The Senate’s latest price setting proposal will undermine U.S. economic growth
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
Biopharmaceutical industry drives economic growth in all 50 states
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Beyond output and employment: The impact of America’s biopharmaceutical industry
Preserving U.S. innovation worldwide is more important than ever
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
America’s global leadership in biopharmaceutical manufacturing
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
What you need to know about H.R. 3
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
Pelosi’s radical plan leaves lung cancer patients behind
Event tomorrow: Maintaining America’s leadership in access and innovation
Pelosi’s radical plan would leave Alzheimer’s patients behind
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
World Trade Month: How we can expand world-class pro-innovation standards
New Report: Advanced manufacturing powering innovative biopharmaceuticals
Clinical trials impact state economies
Biopharmaceutical venture capital is spurring innovation and economic growth
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
Researchers bring focus on science and medicine to California’s capital city
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
New Report: America's biopharmaceutical industry supports 4.7 million jobs
Biopharma leads sustained economic growth driven by IP-intensive industries
New PhRMA resources chock full of biopharma industry facts
New medicines are part of the solution to hold down future health care costs
"On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions"
Economic Impact
Manufacturing
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
"On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions"